Focused On-demand Library for DNA annealing helicase and endonuclease ZRANB3

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our high-tech, dedicated method is applied to construct targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q5FWF4

UPID:

ZRAB3_HUMAN

Alternative names:

Annealing helicase 2; Zinc finger Ran-binding domain-containing protein 3

Alternative UPACC:

Q5FWF4; B3KYA1; B4E375; B5MDI3; D3DP76; E9PBP0; Q53SM1; Q6P2C4; Q8N1P4; Q9H0E8

Background:

DNA annealing helicase and endonuclease ZRANB3, also known as Annealing helicase 2 and Zinc finger Ran-binding domain-containing protein 3, plays a pivotal role in maintaining genome stability. It is essential for the restart of stalled or collapsed replication forks, limiting inappropriate recombination through its endonuclease activity that cleaves replication fork D-loop intermediates, and its annealing helicase activity that prevents replication fork disintegration.

Therapeutic significance:

Understanding the role of DNA annealing helicase and endonuclease ZRANB3 could open doors to potential therapeutic strategies.